术后淋巴水肿得去专病门诊

2017-06-15 江苏省肿瘤医院淋巴水肿门诊副主任护师 羊丽芳 健康时报网

肿瘤治疗后的继发性淋巴水肿约占全部淋巴水肿患者的一半。据统计,乳腺癌生存者中有15%~30%发生继发性上肢淋巴水肿,而妇科癌症患者治疗后28%~47%发生继发性下肢淋巴水肿。所以,缓解肿瘤患者术后的淋巴水肿困扰很重要,建议前往医院淋巴水肿门诊就诊。淋巴水肿是一种慢性进行性发展疾病,目前还不可治愈。如果治疗及时,护理得当,淋巴水肿可以得到缓解。如果因为忽视未及时治疗,淋巴水肿可以造成严重后果,如上肢

肿瘤治疗后的继发性淋巴水肿约占全部淋巴水肿患者的一半。据统计,乳腺癌生存者中有15%~30%发生继发性上肢淋巴水肿,而妇科癌症患者治疗后28%~47%发生继发性下肢淋巴水肿。所以,缓解肿瘤患者术后的淋巴水肿困扰很重要,建议前往医院淋巴水肿门诊就诊。

淋巴水肿是一种慢性进行性发展疾病,目前还不可治愈。如果治疗及时,护理得当,淋巴水肿可以得到缓解。如果因为忽视未及时治疗,淋巴水肿可以造成严重后果,如上肢浮肿、脂肪堆积、纤维化,甚至会糜烂,面临皮肤癌变、截肢等。

淋巴水肿综合治疗包括有淋巴引流、压力治疗、功能锻炼和皮肤护理四部分,患者在进行淋巴综合治疗的时候要注意保护皮肤的完整性,尤其要避免蚊虫叮咬,因为叮咬后容易发生感染进而导致淋巴管炎。在淋巴引流的时候要注意手法轻柔缓慢,一般在医院门诊每次需要40分钟,患者也可以在专业医生的指导下学习后回家自行缓解症状。在医院,淋巴水肿门诊医护人员还会对患者进行运动指导和皮肤护理的相关指导。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=231518, encodeId=47362315188a, content=正在研究该问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5dnicvDOticughRdDibueiaibRzxp5icvQ7EXr3aSxIIfpGFlQ/0, createdBy=e3031710362, createdName=tomoyo89, createdTime=Tue Aug 08 14:59:58 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333362, encodeId=2026133336287, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366594, encodeId=408c136659455, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211271, encodeId=7bd92112e1be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 15 23:47:45 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-08-08 tomoyo89

    正在研究该问题

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=231518, encodeId=47362315188a, content=正在研究该问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5dnicvDOticughRdDibueiaibRzxp5icvQ7EXr3aSxIIfpGFlQ/0, createdBy=e3031710362, createdName=tomoyo89, createdTime=Tue Aug 08 14:59:58 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333362, encodeId=2026133336287, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366594, encodeId=408c136659455, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211271, encodeId=7bd92112e1be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 15 23:47:45 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-17 小华子
  3. [GetPortalCommentsPageByObjectIdResponse(id=231518, encodeId=47362315188a, content=正在研究该问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5dnicvDOticughRdDibueiaibRzxp5icvQ7EXr3aSxIIfpGFlQ/0, createdBy=e3031710362, createdName=tomoyo89, createdTime=Tue Aug 08 14:59:58 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333362, encodeId=2026133336287, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366594, encodeId=408c136659455, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211271, encodeId=7bd92112e1be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 15 23:47:45 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=231518, encodeId=47362315188a, content=正在研究该问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM5dnicvDOticughRdDibueiaibRzxp5icvQ7EXr3aSxIIfpGFlQ/0, createdBy=e3031710362, createdName=tomoyo89, createdTime=Tue Aug 08 14:59:58 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333362, encodeId=2026133336287, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366594, encodeId=408c136659455, content=<a href='/topic/show?id=66b76595ebf' target=_blank style='color:#2F92EE;'>#淋巴水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65957, encryptionId=66b76595ebf, topicName=淋巴水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 17 02:40:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211271, encodeId=7bd92112e1be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 15 23:47:45 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-15 luominglian113

    学习了,谢谢分享

    0

相关资讯

Breast Cancer Res Treat:紫杉烷-化疗不会增加乳腺癌相关淋巴水肿的风险

背景:紫杉烷化疗治疗乳腺癌与四肢液体潴留有关;然而,它与乳腺癌相关的淋巴水肿的发展尚不清楚。我们试图确定辅助剂基于紫杉烷的化疗是否会增加上肢淋巴水肿或轻度肿胀的风险。方法:对1121例单侧乳腺癌患者进行周长测量前瞻性筛查淋巴水肿。从术前基线上看,淋巴水肿定义为相对体积的变化(RVC)≥10%。轻度肿胀定义为RVC 为5 %- < 10%。通过医疗记录审核获得临床病理特征。Kaplan-Mei

BMJ:什么才是乳腺癌患者术后淋巴水肿的更佳保守干预措施?

淋巴水肿是乳腺癌术后的常见并发症,但外科干预措施应用并不广泛,且仅作为重症淋巴水肿的治疗手段,因此临床上常使用保守干预措施。那么,最佳保守干预措施是什么?近期,荷兰癌症研究所理疗科的临诊流行病学家Martijn M Stuiver副教授发表在《BMJ》杂志上的一项研究对此进行了综述。

SCI TRANSL MED:白三烯B4拮抗剂改善实验性淋巴水肿!

综上所述,研究人员发现在疾病中LTB4的浓度处在对淋巴管修复有害的范围。该研究结果表明LTB4是一种很有前途的治疗获得性淋巴水肿的药物靶点。

Br J Surg:CSAL治疗腿部淋巴水肿

腿部的晚期淋巴水肿的治疗是具有挑战性的,尤其是当保守治疗失败,受影响和不受影响腿之间的体积差异变得更大时。四周负压抽脂术(CSAL)已被描述为终末期淋巴水肿腿的治疗选择。在这里,分析CSAL治疗终末期原发性和继发性淋巴水肿腿的长期结果。这是一项关于CSAL治疗单侧慢性不可逆的淋巴水肿的描述性研究。术后恢复压迫疗法。手术前测量腿体积,并在术后1、6、12和24个月后测量腿体积。47例原发性淋巴水肿患

Lancet Oncol:手术范围、超重或肥胖影响术后乳腺癌患者上臂淋巴水肿的发病率

在过去的几十年中,与乳腺癌相关的淋巴水肿的发病率和发病危险因素相关的证据得到了长足的发展,质量也有所改善。来自澳大利亚昆士兰科技大学的Tracey DiSipio等评估了乳腺癌术后单侧上臂淋巴水肿的发病率,以及探究了与淋巴水肿发生相关的可能危险因素,他们的研究结果发表在Lancet Oncol 3月的在线期刊上。研究者检索的数据库为Academic Search Elite、Cumulative